DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouska, J. J.
Right arrow Articles by Carter, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouska, J. J.
Right arrow Articles by Carter, G. W.

0090-9556/97/2509-1032-1038$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 9


ARTICLE
Improving the In Vivo Duration of 5-Lipoxygenase Inhibitors
Application of an In Vitro Glucuronosyltransferase Assay

Jennifer J. Bouska, Randy L. Bell, Carole L. Goodfellow, Andrew O. Stewart, Clint D. W. Brooks, and George W. Carter

Immunoscience Research, Pharmaceutical Products Division, Abbott Laboratories

An in vitro glucuronidation assay was used to optimize a series of N-hydroxyurea-containing 5-lipoxygenase inhibitors for metabolic stability. The glucuronidation of these compounds in cynomolgus monkey microsomes followed Michaelis-Menten kinetics allowing calculation of Vmax and KM. The Vmax values ranged from 0.02 to 7.9 nmol/min/mg microsomal protein, a 400-fold difference, whereas KM ranged from 204 to 2500 µM, only a 12-fold difference. In vitro intrinsic clearance values (CLint) were calculated for 18 compounds tested in the kinetic assay and compared with the in vivo plasma clearance (CLp) calculated from intravenous studies done in cynomolgus monkeys. These initial results suggested a relationship between the in vitro CLint and in vivo duration as defined by CLp. A more rapid in vitro assay was developed in a 96-well format using a single concentration of substrate (100 µM) from which a glucuronidation rate was calculated. The results from this assay for 40 compounds correlated with in vivo plasma clearance (r = 0.57). This more efficient assay was used to test more than 100 compounds and develop structure-metabolism relationships based on metabolic stability and improved duration. The culmination of this effort contributed to the discovery of ABT-761, a 5-lipoxygenase inhibitor with in vivo duration in monkey improved 40-fold over the first generation inhibitor. Further studies performed in human liver microsomes demonstrated a similar trend that was corroborated by the 8-fold increase in duration after oral dosing in humans observed with ABT-761.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
I. J. Martin, R. J. Lewis, M. A. Bernstein, I. G. Beattie, C. A. Martin, R. J. Riley, and B. Springthorpe
Which Hydroxy? Evidence for Species Differences in the Regioselectivity of Glucuronidation in Rat, Dog, and Human in Vitro Systems and Dog in Vivo
Drug Metab. Dispos., September 1, 2006; 34(9): 1502 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. V. Balakin, S. Ekins, A. Bugrim, Y. A. Ivanenkov, D. Korolev, Y. V. Nikolsky, A. A. Ivashchenko, N. P. Savchuk, and T. Nikolskaya
QUANTITATIVE STRUCTURE-METABOLISM RELATIONSHIP MODELING OF METABOLIC N-DEALKYLATION REACTION RATES
Drug Metab. Dispos., October 1, 2004; 32(10): 1111 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. B. Fisher, K. Campanale, B. L. Ackermann, M. VandenBranden, and S. A. Wrighton
In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin
Drug Metab. Dispos., May 1, 2000; 28(5): 560 - 566.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.